We demonstrated that RBM15/IGF2BP1-mediated m6A modification of MEF2A upregulated its expression to promote PD-L1 transcription, which stabilized SOX12 mRNA and then weakened cetuximab sensitivity in CRC. The gene discussed is MEF2A; the disease is colorectal carcinoma.